These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

558 related articles for article (PubMed ID: 31643072)

  • 1. Vaccination for quality of life: herpes-zoster vaccines.
    Lang PO; Aspinall R
    Aging Clin Exp Res; 2021 Apr; 33(4):1113-1122. PubMed ID: 31643072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Public Health Impact and Cost-Effectiveness of Non-live Adjuvanted Recombinant Zoster Vaccine in Canadian Adults.
    McGirr A; Van Oorschot D; Widenmaier R; Stokes M; Ganz ML; Jung H; Varghese L; Curran D
    Appl Health Econ Health Policy; 2019 Oct; 17(5):723-732. PubMed ID: 31250218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Public health impact of herpes zoster vaccination on older adults in Hong Kong.
    Chan PKS; Wong MCS; Chan M; Ching K; Giannelos N; Ng C
    Hum Vaccin Immunother; 2023 Dec; 19(1):2176065. PubMed ID: 36854447
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of Recombinant Zoster Vaccine (RZV) and Varicella Vaccine Live (VVL) against herpes zoster and post-herpetic neuralgia among adults aged 65 and over in Japan.
    Hoshi SL; Seposo X; Shono A; Okubo I; Kondo M
    Vaccine; 2019 Jun; 37(27):3588-3597. PubMed ID: 31153691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.
    Oh H; Tan C; Williams C; Giannelos N; Ng C
    Hum Vaccin Immunother; 2024 Dec; 20(1):2348839. PubMed ID: 38804600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of adjuvanted recombinant zoster vaccine and its implications for shingles prevention.
    Lecrenier N; Beukelaers P; Colindres R; Curran D; De Kesel C; De Saegher JP; Didierlaurent AM; Ledent EY; Mols JF; Mrkvan T; Normand-Bayle M; Oostvogels L; Da Silva FT; Vassilev V; Vinals C; Brecx A
    Expert Rev Vaccines; 2018 Jul; 17(7):619-634. PubMed ID: 30028651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review.
    Giannelos N; Ng C; Curran D
    Hum Vaccin Immunother; 2023 Dec; 19(1):2168952. PubMed ID: 36916240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Public health impact model estimating the impact of introducing an adjuvanted recombinant zoster vaccine into the UK universal mass vaccination programme.
    van Oorschot DAM; Hunjan M; Bracke B; Lorenc S; Curran D; Starkie-Camejo H
    BMJ Open; 2019 May; 9(5):e025553. PubMed ID: 31061027
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Vaccination against herpes zoster].
    Larsen CS; Helleberg M
    Ugeskr Laeger; 2021 Nov; 183(47):. PubMed ID: 34851258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How large could the public health impact of introducing recombinant zoster vaccination for people aged ≥50 years in five Latin American countries be?
    Han R; Gomez JA; de Veras B; Pinto T; Guzman-Holst A; Nieto J; van Oorschot DAM
    Hum Vaccin Immunother; 2023 Dec; 19(1):2164144. PubMed ID: 36821856
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations.
    Prosser LA; Harpaz R; Rose AM; Gebremariam A; Guo A; Ortega-Sanchez IR; Zhou F; Dooling K
    Ann Intern Med; 2019 Mar; 170(6):380-388. PubMed ID: 30776797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The comparative efficacy and safety of herpes zoster vaccines: A network meta-analysis.
    McGirr A; Widenmaier R; Curran D; Espié E; Mrkvan T; Oostvogels L; Simone B; McElhaney JE; Burnett H; Haeussler K; Thano A; Wang X; Newson RS
    Vaccine; 2019 May; 37(22):2896-2909. PubMed ID: 30982636
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant zoster vaccine in immunocompetent and immunocompromised adults: A review of clinical studies.
    Mwakingwe-Omari A; Lecrenier N; Naficy A; Curran D; Posiuniene I
    Hum Vaccin Immunother; 2023 Dec; 19(3):2278362. PubMed ID: 37965770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination against herpes zoster in developed countries: state of the evidence.
    Drolet M; Oxman MN; Levin MJ; Schmader KE; Johnson RW; Patrick D; Mansi JA; Brisson M
    Hum Vaccin Immunother; 2013 May; 9(5):1177-84. PubMed ID: 23324598
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes zoster in Belgium: a new solution to an old problem.
    Nikkels AF; Schoevaerdts D; Kauffmann F; Strubbe F; Bensemmane S
    Acta Clin Belg; 2024 Jun; 79(3):205-216. PubMed ID: 38781037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Herpes zoster vaccine: A health economic evaluation for Switzerland.
    Blank PR; Ademi Z; Lu X; Szucs TD; Schwenkglenks M
    Hum Vaccin Immunother; 2017 Jul; 13(7):1495-1504. PubMed ID: 28481678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of varicella vaccine against herpes zoster and post-herpetic neuralgia for elderly in Japan.
    Hoshi SL; Kondo M; Okubo I
    Vaccine; 2017 May; 35(24):3264-3271. PubMed ID: 28479176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential cost-effectiveness of vaccination against herpes zoster and post-herpetic neuralgia.
    Brisson M; Pellissier JM; Camden S; Quach C; De Wals P
    Hum Vaccin; 2008; 4(3):238-45. PubMed ID: 18382137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes Zoster and Postherpetic Neuralgia: a review of the effects of vaccination.
    Johnson RW
    Aging Clin Exp Res; 2009 Jun; 21(3):236-43. PubMed ID: 19571648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A systematic review of the cost effectiveness of herpes zoster vaccination.
    Szucs TD; Pfeil AM
    Pharmacoeconomics; 2013 Feb; 31(2):125-36. PubMed ID: 23335045
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.